Analyses of cancer data from three ezetimibe trials.

Journal article

BACKGROUND: Five years of statin therapy lowers low-density lipoprotein (LDL) cholesterol substantially and, over a 5-year period, results in reductions in the incidence of cardiovascular events. The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial (ClinicalTrials.gov number, NCT00092677) has raised the hypothesis that adding ezetimibe to statin therapy for larger LDL cholesterol reductions might increase the incidence of cancer. METHODS: We compared the results of a hypothesis-gener...

Expand abstract

Authors: Peto, R; Emberson, J; Landray, M; Baigent, C; Collins, R

• Publication status: Published
• Journal: New England journal of medicine
• Volume: 359
• Issue: 13
• Pages: 1357-1366
• Publication date: 2008-09-01
• DOI: 10.1056/nejmsa0806603
• EISSN: 1533-4406
• ISSN: 0028-4793
• Language: English
• Keywords: Neoplasms; Cholesterol, LDL; Aortic Valve Stenosis; Simvastatin; Randomized Controlled Trials as Topic; Drug Therapy, Combination; Hypercholesterolemia; Incidence; Risk; Azetidines; Follow-Up Studies; Anticholesteremic Agents; Humans